This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase inhibitors or fulvestrant in the a/mBC community oncology setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of patients receiving various cancer treatment regimens
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Proportion of patients receiving each therapy sequence across lines
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Treatment persistence
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Progression Free Survival (PFS)
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Overall Survival (OS)
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Tumor response rate
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Proportion of patients that experience dose adjustment
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)
Proportion of patients who discontinue therapy
Timeframe: A/MBC diagnosis through end of study (assessed up to 24 months)